Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLATE Vaccine with Checkpoint Inhibitors in Advanced Solid Tumors
NCT03953235Phase 2Completed
- Sponsor
- Gritstone bio, Inc.
- Start
- Jul 2019
- Primary completion
- Mar 2023
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of GRT-C903 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC) and 1 more (2 arms), sponsored by Gritstone bio, Inc. Primary endpoints: Incidence of adverse events, serious adverse events, and dose limiting toxicities, Objective Response Rate up to 27 months and 1 more. Started Jul 2019; status: completed.
02
Drugs
GRT-C903
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT03953235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953235.